Guicheng Wu

机构：Central South University, Chongqing University, China Tobacco, Southwest Medical University, Affiliated Hospital of Southwest Medical University, Nanfang Hospital, Precision for Medicine (United States), Chongqing Three Gorges Central Hospital, Baoshan University, Chongqing Three Gorges University, Southern Medical University · ORCID：0000-0003-4220-0767

发表论文 62 篇 · 总被引 1498 次 · h-index 18

代表论文

• Mitochondrial dysfunction in vascular endothelial cells and its role in atherosclerosis (2022 · Frontiers in Physiology · 被引 114)
• Preparation of Pueraria lobata Root-Derived Exosome-Like Nanovesicles and Evaluation of Their Effects on Mitigating Alcoholic Intoxication and Promoting Alcohol Metabolism in Mice (2024 · International Journal of Nanomedicine · 被引 50)
• A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease (2024 · Hepatology International · 被引 33)
• A Macrophage Membrane‐Functionalized, Reactive Oxygen Species‐Activatable Nanoprodrug to Alleviate Inflammation and Improve the Lipid Metabolism for Atherosclerosis Management (2024 · Advanced Healthcare Materials · 被引 23)
• 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients (2022 · Journal of Clinical and Translational Hepatology · 被引 22)
• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 20)